Opus Genetics (IRD) Non Operating Investment Income (2020 - 2026)
Opus Genetics (IRD) reported Non Operating Investment Income of -$51.4 million for Q1 2026, down 1931.16% year-over-year from $2.8 million in Q1 2025, and down 799.23% on a QoQ basis from -$5.7 million in Q4 2025.
Opus Genetics (IRD) has 6 years of Non Operating Investment Income data on file, last reported at -$51.4 million in Q1 2026.
- Quarterly Non Operating Investment Income fell 1931.16% year-over-year to -$51.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$65.7 million (down 2383.07% YoY) and the FY2025 annual result came in at -$11.5 million, down 16093.06% from the prior year.
- Non Operating Investment Income declined to -$51.4 million in Q1 2026 per IRD's latest filing, from -$5.7 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $2.8 million in Q1 2025 and bottomed at -$51.4 million in Q1 2026.
- The 4-year median for Non Operating Investment Income is $40000.0 (2023), against an average of -$7.8 million.
- The widest annual swing landed in 2024, when Non Operating Investment Income surged 278.95%; it then slumped 8033.33% in 2025.
- Tracing IRD's Non Operating Investment Income over 4 years: stood at $19000.0 in 2023, then surged by 278.95% to $72000.0 in 2024, then tumbled by 8033.33% to -$5.7 million in 2025, then plunged by 799.23% to -$51.4 million in 2026.
- Per Business Quant, the three latest IRD Non Operating Investment Income figures stand at -$51.4 million (Q1 2026), -$5.7 million (Q4 2025), and -$9.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -51.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.36 Mn |
| Mar 31, 2026 | -51.36 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -9.53 Mn |
| Sep 30, 2025 | -9.53 Mn |
| Jun 30, 2025 | 917,000.00 |
| Jun 30, 2025 | 917,000.00 |
| Mar 31, 2025 | 2.81 Mn |
| Mar 31, 2025 | 2.81 Mn |
| Dec 31, 2024 | 72,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | 61,000.00 |
| Sep 30, 2023 | 61,000.00 |
| Mar 31, 2021 | -33.83 Mn |
| Mar 31, 2021 | -33.83 Mn |
| Dec 31, 2020 | -1.64 Mn |
| Dec 31, 2020 | -1.64 Mn |
| Sep 30, 2020 | 879,000.00 |
| Sep 30, 2020 | 879,000.00 |
| Jun 30, 2020 | -919,000.00 |
| Jun 30, 2020 | -919,000.00 |
| Mar 31, 2020 | 198,000.00 |
| Mar 31, 2020 | 198,000.00 |